文献速递类风湿关节炎

肥胖类风湿关节炎患者减重干预后结局改善:随机试验

Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

这项概念验证、12周、单盲随机对照试验纳入肥胖(BMI≥30)且DAS28≥3.2、伴能量多普勒滑膜炎证据的类风湿关节炎患者40例,随机分为低热量饮食干预组(n=20)与对照组(n=20)。干预组平均减重9.5 kg,对照组0.5 kg(P<0.001);RAPID3、瘦素、脂联素组内及组间均显著改善(均P<0.03),DAS28组内由5.2降至4.2,组间差异未达统计学显著。

要点

  • 饮食干预组平均减重9.5 kg,对照组0.5 kg(P<0.001)。
  • RAPID3、瘦素、脂联素在组内及组间均显著改善(均P<0.03)。
  • DAS28组内由5.2降至4.2(P<0.001),组间差异未达统计学显著。

核心结论

  • 肥胖类风湿关节炎患者接受饮食干预实现了减重,RAPID3、脂联素和瘦素水平组间显著改善,DAS28和HAQ-DI呈阳性趋势。

研究设计与样本

  • 概念验证、12周、单盲、随机对照试验,纳入BMI≥30、DAS28≥3.2且伴能量多普勒滑膜炎证据的肥胖类风湿关节炎患者40例。
  • 随机分为低热量饮食干预组(n=20)与对照组(n=20),饮食干预为每日1000-1500 kcal低热量饮食加高蛋白代餐。
  • 研究提前终止招募,所有分析基于意向性治疗,显著性水平0.05。

主要发现

  • 饮食干预组平均减重9.5 kg,对照组0.5 kg(P<0.001)。
  • RAPID3改善、血清瘦素下降、血清脂联素升高在饮食干预组内及组间均显著(均P<0.03)。
  • DAS28在饮食干预组内由5.2降至4.2(P<0.001;组间差值-0.51[95%CI -1.01, 0.00],P=0.056)。
  • HAQ-DI在饮食干预组内显著改善(P<0.04;组间P=0.065)。
  • 超声指标与多生物标志物疾病活动度评分组间无差异(PDUS-34差值-2.0[95%CI -7.00, 3.1],组间P=0.46)。

关键数值与推荐

  • 共同主要结局为DAS28变化与能量多普勒超声(PDUS)-34变化。
  • 饮食干预组DAS28由5.2降至4.2(P<0.001),组间差值-0.51(95%CI -1.01, 0.00),P=0.056,未达统计学显著。
  • PDUS-34组间差值-2.0(95%CI -7.00, 3.1),P=0.46,未达统计学显著。

临床怎么用

  • 作者认为,需要更长期、更大规模的减重研究来验证这些发现,并据此进一步开展改善肥胖类风湿关节炎患者临床管理的研究。

局限性

  • 研究提前终止招募。
  • 作者指出需要更长期、更大规模减重研究来验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether a weight loss intervention programme improves RA disease activity and/or musculoskeletal ultrasound synovitis measures in obese RA patients. METHODS: We conducted a proof-of-concept, 12-week, single-blind, randomized controlled trial of obese RA patients (BMI ≥ 30) with 28-joint DAS (DAS28) ≥ 3.2 and with evidence of power Doppler synovitis. Forty patients were randomized to the diet intervention (n = 20) or control group (n = 20). Diet intervention consisted of a hypocaloric diet of 1000-1500 kcal/day and high protein meal replacements. Co-primary outcomes included change in DAS28 and power Doppler ultrasound (PDUS)-34. Clinical disease activity, imaging, biomarkers, adipokines and patient-reported outcomes were monitored throughout the trial. Recruitment terminated early. All analyses were based on intent-to-treat for a significance level of 0.05. RESULTS: The diet intervention group lost an average 9.5 kg/patient, while the control group lost 0.5 kg (P < 0.001). Routine Assessment of Patient Index Data 3 (RAPID3) improved, serum leptin decreased and serum adiponectin increased significantly within the diet group and between the groups (all P < 0.03). DAS28 decreased, 5.2 to 4.2, within the diet group (P < 0.001; -0.51 [95% CI -1.01, 0.00], P = 0.056, between groups). HAQ-Disability Index (HAQ-DI) improved significantly within the diet group (P < 0.04; P = 0.065 between group). Ultrasound measures and the multi-biomarker disease activity score did not differ between groups (PDUS-34 -2.0 [95% CI -7.00, 3.1], P = 0.46 between groups). CONCLUSION: Obese RA patients on the diet intervention achieved weight loss. There were significant between group improvements for RAPID3, adiponectin and leptin levels, and positive trends for DAS28 and HAQ-DI. Longer-term, larger weight loss studies are needed to validate these findings, and will allow for further investigative work to improve the clinical management of obese RA patients. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02881307.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ranganath VK, La Cava A, Vangala S, et al. Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Rheumatology (Oxford). 2023. PMID: 35640116. doi:10.1093/rheumatology/keac307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。